z-logo
Premium
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study
Author(s) -
Rosenstock J.,
Wilson C.,
Fleck P.
Publication year - 2013
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12102
Subject(s) - alogliptin , glipizide , medicine , diabetes mellitus , type 2 diabetes , type 2 diabetes mellitus , pharmacology , gastroenterology , endocrinology , dipeptidyl peptidase 4
Aim To prospectively evaluate the efficacy and safety of alogliptin versus glipizide in elderly patients with type 2 diabetes mellitus ( T2DM ) over 1 year of treatment. Methods This was a randomized, double‐blind, active‐controlled study of elderly T2DM patients (aged 65–90 years) with mild hyperglycaemia on diet/exercise therapy alone [glycosylated haemoglobin ( HbA1c ) 6.5–9.0%] or plus oral antidiabetic monotherapy ( HbA1c 6.5–8.0%). Patients were randomized to once‐daily alogliptin 25 mg or glipizide 5 mg titrated to 10 mg, if needed. Hypoglycaemic episodes were systematically captured under predefined criteria. Results In the primary analysis, HbA1c mean changes from a baseline of 7.5% were −0.14% with alogliptin (n = 222) and −0.09% with glipizide (n = 219) at the end of the study, demonstrating non‐inferiority of alogliptin to glipizide [least squares ( LS ) mean difference = −0.05%; one‐sided 97.5% confidence interval ( CI ): −∞, 0.13%]. More clinically relevant HbA1c reductions occurred among patients who completed the study: −0.42 and −0.33% with alogliptin and glipizide, with non‐inferiority again confirmed ( LS mean difference = −0.09%; one‐sided 97.5% CI : −∞, 0.07%). Overall, alogliptin was safe and well tolerated, with notably fewer hypoglycaemic episodes than glipizide [5.4% (31 episodes) vs. 26.0% (232 episodes), respectively]; three patients experienced severe hypoglycaemia, all with glipizide. Alogliptin also resulted in favourable weight changes versus glipizide (−0.62 vs. 0.60 kg at week 52; p < 0.001). Conclusions Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here